findings of a reduction in IgA 1 plasma cells in a small subgroup of patients with IgAN who were treated with prednisone, while no reduction in GdIgA1 1 cells was observed. It would be fascinating to assess dynamic changes in GdIgA1 1 B-cell populations in response to the mucosal-directed therapies that are being developed in this condition. Indeed, early studies of targeted-release formulation (TRF) budesonide (the first US Food and Drug Administration-approved treatment for IgAN that specifically targets gut-associated lymphoid tissue), BION-1301 (an anti-APRIL mAb), and atacicept (a recombinant fusion protein containing the binding portion of transmembrane activator and CAML interactor (TACI) that inhibits both BAFF and APRIL) have each been demonstrated to reduce GdIgA1 levels in IgAN. [7][8][9] In contrast, depletion of peripheral CD20 1 B cells with rituximab did not affect GdIgA1 levels, which is likely due to GdIgA1-secreting plasma cells not being targeted by this approach. 10 Further characterization of circulating GdIgA1 1 B-cell populations, as well as improving our understanding of the pathogenesis, could eventually lead to their use as a biomarker to assess response to therapy or to the identification of new therapeutic targets.